Beryl Manning-Geist

Beryl Manning-Geist

Auto-generated profile, based on publicly available information

Beryl Manning-Geist

Emory University School of Medicine/Winship Cancer Institute, Atlanta, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BMBeryl Manning-Geist
Beryl Manning-Geist
SGSushmita Gordhandas
Sushmita Gordhandas
YLYing L. Liu
Ying L. Liu
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
RGRachel Grisham
Rachel Grisham
Purpose: To characterize the somatic mutational landscape, investigate associations between genetic alterations and clinical outcomes, and determine the prevalence of pathogenic germline mutations in low-grade serous ovarian carcinomas (LGSC). Experimental Design: Patients with LGSC tumors who underwent panel-based sequencing of up to 505 genes were identified. Data on somatic and germline mutations; copy-number alterations; and clinicopathologic features, including age at diagnosis, platinum sensitivity, and overall survival (OS), were collected. Results: Following central pathology rereview, 119 patients with LGSC were identified for analysis. Of these, 110 (92%) had advanced-stage disease (stages III/IV). Somatic KRAS (33%), NRAS (11%), EIF1AX (10%), and BRAF (11%) alterations were the most common; MAPK pathway alterations were found in 60% (n = 71) of LGSCs. KRAS mutations were significantly associated with age at diagnosis more than 50 years (P = 0.02) and platinum-sensitive disease (P = 0.03). On multivariate analysis, MAPK pathway alterations (P = 0.02) and platinum sensitivity (P = 0.005) were significantly associated with improved OS. Seventy-nine patients (66%) underwent germline genetic testing; seven pathogenic germline mutations were identified: MUTYH (n = 2), BAP1 (n = 1), RB1 (n = 1), CHEK2 (n = 1), APC (n = 1), and FANCA (n = 1). There were no germline BRCA1/2 mutations. One germline MUTYH-associated LGSC harbored loss-of-heterozygosity at the MUTYH locus, and the patient with the germline BAP1 mutation also harbored a somatic BAP1 frameshift mutation. Conclusions: This study showed that MAPK pathway alterations in LGSC, including KRAS mutations, are independently associated with platinum sensitivity and prolonged survival. Germline data, which were limited, identified few pathogenic germline mutations in patients with LGSC. See related commentary by Veneziani and Oza, p. 4357

18 July 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BMBeryl L. Manning-Geist
Beryl L. Manning-Geist
YLYing L. Liu
Ying L. Liu
KDKelly A. Devereaux
Kelly A. Devereaux
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
QZQin C. Zhou
Qin C. Zhou
BWBritta Weigelt
Britta Weigelt
Purpose: Microsatellite instability–high (MSI-H) endometrial carcinomas are underpinned by distinct mechanisms of DNA mismatch repair deficiency (MMR-D). We sought to characterize the clinical and genetic features of MSI-H endometrial cancers harboring germline or somatic mutations in MMR genes or MLH1 promoter hypermethylation (MLH1ph). Experimental Design: Of > 1,100 patients with endometrial cancer that underwent clinical tumor-normal sequencing, 184 had MSI-H endometrial cancers due to somatic MMR mutations or MLH1ph, or harbored pathogenic germline MMR mutations. Clinicopathologic features, mutational landscape, and tumor-infiltrating lymphocyte (TIL) scores were compared among MMR-D groups using nonparametric tests. Log-rank tests were used for categorical associations; Kaplan–Meier method and Wald test based on Cox proportional hazards models were employed for continuous variables and survival analyses. Results: Compared with patients with germline (n = 25) and somatic (n = 39) mutations, patients with MLH1ph endometrial cancers (n = 120) were older (P < 0.001), more obese (P = 0.001) and had more advanced disease at diagnosis (P = 0.025). MLH1ph endometrial cancers were enriched for JAK1 somatic mutations as opposed to germline MMR-D endometrial cancers which showed enrichment for pathogenic ERBB2 mutations. MLH1ph endometrial cancers exhibited lower tumor mutational burden and TIL scores compared with endometrial cancers harboring germline or somatic MMR mutations (P < 0.01). MLH1ph endometrial cancer patients had shorter progression-free survival (PFS) on univariate analysis, but in multivariable models, stage at diagnosis remained the only predictor of survival. For stage I/II endometrial cancer, two-year PFS was inferior for patients with MLH1ph endometrial cancers compared with germline and somatic MMR groups (70% vs. 100%, respectively). Conclusions: MLH1ph endometrial cancers likely constitute a distinct clinicopathologic entity compared with germline and somatic MMR-D ECs with potential treatment implications.

11 December 2021 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
EAEmeline M. Aviki
Emeline M. Aviki
BMBeryl L. Manning-Geist
Beryl L. Manning-Geist
SSStefania S. Sokolowski
Stefania S. Sokolowski
TNTiffanny Newman
Tiffanny Newman
VBVictoria S. Blinder
Victoria S. Blinder
NANadeem R. Abu-Rustum
Nadeem R. Abu-Rustum

23 May 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
TSTiffany Y Sia
Tiffany Y Sia
BMBeryl Manning-Geist
Beryl Manning-Geist
SGSushmita Gordhandas
Sushmita Gordhandas
RMRajmohan Murali
Rajmohan Murali
AMAntonio Marra
Antonio Marra
DZDmitriy Zamarin
Dmitriy Zamarin
Background Although immune checkpoint blockade has demonstrated limited effectiveness against ovarian cancer, subset analyses from completed trials suggest possible superior efficacy in the clear cell carcinoma subtype. Objective To describe the outcomes of patients with ovarian clear cell carcinoma treated with immune checkpoint blockade. Methods This was a single-institution, retrospective case series of patients with ovarian clear cell carcinoma treated with a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor with or without concomitant cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibition between January 2016 and June 2021. Demographic variables, tumor microenvironment, molecular data, and clinical outcomes were examined. Time to treatment failure was defined as the number of days between start of treatment and next line of treatment or death. Results A total of 16 eligible patients were analyzed. The median treatment duration was 56 days (range 14–574); median time to treatment failure was 99 days (range 27–1568). The reason for discontinuation was disease progression in 88% of cases. Four patients (25%) experienced durable clinical benefit (time to treatment failure ≥180 days). One patient was treated twice with combined immune checkpoint blockade and experienced a complete response each time. All 12 patients who underwent clinical tumor-normal molecular profiling had microsatellite-stable disease, and all but one had low tumor mutation burden. Multiplex immunofluorescence analysis available from pre-treatment biopsies of two patients with clinical benefit demonstrated abundant tumor-infiltrating lymphocytes expressing PD-1. Conclusion Our study suggests a potential role for immune checkpoint blockade in patients with clear cell carcinoma of the ovary. Identification of genetic and microenvironmental biomarkers predictive of response will be key to guide therapy.

1 October 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
BMBeryl L. Manning-Geist
Beryl L. Manning-Geist
KHKatherine Hicks-Courant
Katherine Hicks-Courant
AGAllison A. Gockley
Allison A. Gockley
RCRachel M. Clark
Rachel M. Clark
MCMarcela G. Del Carmen
Marcela G. Del Carmen
MWMichael J. Worley
Michael J. Worley

25 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BMBeryl L. Manning-Geist
Beryl L. Manning-Geist
SGSacha Gnjatic
Sacha Gnjatic
CACarol Aghajanian
Carol Aghajanian
JKJason A. Konner
Jason A. Konner
SKSarah H. Kim
Sarah H. Kim
RORoisin O'cearbhaill
Roisin O'cearbhaill
We examined the safety and immunogenicity of sequential administration of a tetravalent, non-HLA (human leukocyte antigen) restricted, heteroclitic Wilms’ Tumor 1 (WT1) peptide vaccine (galinpepimut-S) with anti–PD-1 (programmed cell death protein 1) nivolumab. This open-label, non-randomized phase I study enrolled patients with WT1-expressing ovarian cancer in second or third remission from June 2016 to July 2017. Therapy included six (every two weeks) subcutaneous inoculations of galinpepimut-S vaccine adjuvanted with Montanide, low-dose subcutaneous sargramostim at the injection site, with intravenous nivolumab over 12 weeks, and up to six additional doses until disease progression or toxicity. One-year progression-free survival (PFS) was correlated to T-cell responses and WT1-specific immunoglobulin (Ig)G levels. Eleven patients were enrolled; seven experienced a grade 1 adverse event, and one experienced a grade ≥3 adverse event considered a dose-limiting toxicity. Ten (91%) of eleven patients had T-cell responses to WT1 peptides. Seven (88%) of eight evaluable patients had IgG against WT1 antigen and full-length protein. In evaluable patients who received >2 treatments of galinpepimut-S and nivolumab, the 1-year PFS rate was 70%. Coadministration of galinpepimut-S and nivolumab demonstrated a tolerable toxicity profile and induced immune responses, as indicated by immunophenotyping and WT1-specific IgG production. Exploratory analysis for efficacy yielded a promising 1-year PFS rate.